Glenmark Pharma Shares Surge as Subsidiary Licenses Cancer Drug to AbbVie for $700 Million Upfront
Glenmark Pharma has attracted significant investor attention following a major licensing deal between its subsidiary and global pharmaceutical company AbbVie. The subsidiary has licensed a promising cancer drug to AbbVie for an upfront payment of $700 million, [...]